Investor Relations

About Synapse Biomedical

Synapse Biomedical Inc. (SBI) was founded in September 2002 to commercialize the NeuRx® Diaphragm Pacing System (DPS) which has been developed during a twenty-year period, in collaboration with Case Western Reserve University and the University Hospitals of Cleveland. The innovative research performed at these institutions has led to significant advances in state-of-the-art electrical stimulation for the treatment of chronic respiratory insufficiency.

Utilizing the Power of the NeuRx DPS®

This innovation allows clinicians to reach beyond current methods of treatment to meet the ventilatory needs of people dependent on mechanical ventilation due to spinal cord injuries and to provide diaphragm conditioning for patients with ALS.

Our Culture

Our culture is best described by its people: smart, driven, energetic and committed to improve the lives of individuals with neurological impairment, such as spinal cord injury, Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig’s disease and others.

Our Mission

Synapse Biomedical (SBI) is dedicated to the research, development and commercialization of life-altering neurostimulation products. The pioneering of this technology will allow the global healthcare community to reach beyond current methods of treatment and provide a new standard of care to improve patient outcomes.

Synapse Biomedical, Inc. has received an Emergency Use Authorization for the emergency use of its TransAeris DPS...